JP2019517828A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517828A5 JP2019517828A5 JP2019518374A JP2019518374A JP2019517828A5 JP 2019517828 A5 JP2019517828 A5 JP 2019517828A5 JP 2019518374 A JP2019518374 A JP 2019518374A JP 2019518374 A JP2019518374 A JP 2019518374A JP 2019517828 A5 JP2019517828 A5 JP 2019517828A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- clostridium
- purified
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 20
- 241000193163 Clostridioides difficile Species 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 241000428313 Anaerotruncus colihominis Species 0.000 claims 3
- 241001464894 Blautia producta Species 0.000 claims 3
- 241000016537 Dorea longicatena Species 0.000 claims 3
- 241001246487 [Clostridium] bolteae Species 0.000 claims 3
- 241000193462 [Clostridium] innocuum Species 0.000 claims 3
- 241000193450 [Clostridium] symbiosum Species 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000009105 vegetative growth Effects 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022172637A JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2024074166A JP2024109615A (ja) | 2016-06-14 | 2024-05-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349914P | 2016-06-14 | 2016-06-14 | |
| US62/349,914 | 2016-06-14 | ||
| PCT/US2017/037498 WO2017218680A1 (en) | 2016-06-14 | 2017-06-14 | Treatment of clostridium difficile infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172637A Division JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517828A JP2019517828A (ja) | 2019-06-27 |
| JP2019517828A5 true JP2019517828A5 (enExample) | 2020-07-27 |
| JP7168558B2 JP7168558B2 (ja) | 2022-11-09 |
Family
ID=60664224
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019518374A Active JP7168558B2 (ja) | 2016-06-14 | 2017-06-14 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2022172637A Active JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2024074166A Pending JP2024109615A (ja) | 2016-06-14 | 2024-05-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022172637A Active JP7483828B2 (ja) | 2016-06-14 | 2022-10-27 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
| JP2024074166A Pending JP2024109615A (ja) | 2016-06-14 | 2024-05-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12390498B2 (enExample) |
| EP (2) | EP3468573B1 (enExample) |
| JP (3) | JP7168558B2 (enExample) |
| KR (4) | KR102658297B1 (enExample) |
| CN (1) | CN109562133A (enExample) |
| AU (2) | AU2017285211B2 (enExample) |
| CA (2) | CA3027917C (enExample) |
| DK (1) | DK3468573T5 (enExample) |
| ES (1) | ES2960053T3 (enExample) |
| FI (1) | FI3468573T3 (enExample) |
| MX (2) | MX2018015522A (enExample) |
| PT (1) | PT3468573T (enExample) |
| WO (1) | WO2017218680A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018015522A (es) | 2016-06-14 | 2019-07-12 | Vedanta Biosciences Inc | Tratamiento de infeccion por clostridium difficile. |
| EP3606325B1 (en) | 2017-04-03 | 2024-09-04 | Gusto Global, LLC | Rational design of microbial-based biotherapeutics |
| WO2019089643A1 (en) | 2017-10-30 | 2019-05-09 | Seres Therapeutics, Inc. | Compositions and methods for treating antibiotic resistance |
| CN111526882A (zh) * | 2017-11-09 | 2020-08-11 | 韦丹塔生物科学股份有限公司 | 用于治疗变态反应的组合物和方法 |
| US12053495B2 (en) | 2017-12-11 | 2024-08-06 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| BR112020019979A2 (pt) * | 2018-03-29 | 2021-03-09 | Seres Therapeutics, Inc. | Composições e métodos para tratamento de doenças inflamatórias intestinais |
| AU2019289190A1 (en) * | 2018-06-19 | 2021-01-07 | 4D Pharma Research Ltd | Dosage form comprising a live biotherapeutic product |
| AU2019321681A1 (en) * | 2018-08-17 | 2021-02-25 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| IL265735A (en) | 2019-03-31 | 2019-05-30 | Biomica | A microbial consortium and its uses |
| EP3999029A4 (en) * | 2019-07-17 | 2023-07-26 | University of Utah Research Foundation | CLOSTRIDIA CONSORTIA COMPOSITIONS AND METHODS OF TREATMENT OF OBESITY, METABOLIC SYNDROME AND IRRITABLE BOWEL |
| GB201911728D0 (en) * | 2019-08-15 | 2019-10-02 | Genome Res Ltd | Bacterial composistions for the treatment of disease |
| EP3858363A1 (en) | 2020-01-28 | 2021-08-04 | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement | Composition for treating intestinal or pulmonary diseases |
| US20230138517A1 (en) * | 2020-02-07 | 2023-05-04 | Dupont Nutrition Biosciences Aps | Feed compositions for animal health |
| GB202007452D0 (en) * | 2020-05-19 | 2020-07-01 | Microbiotica Ltd | Threrapeutic bacterial composition |
| KR102617297B1 (ko) | 2020-08-21 | 2023-12-27 | 서울대학교산학협력단 | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 |
| KR102269966B1 (ko) * | 2021-01-12 | 2021-06-28 | 주식회사 바이오뱅크힐링 | 루미노코쿠스 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102296288B1 (ko) * | 2020-12-31 | 2021-09-01 | 주식회사 바이오뱅크힐링 | 락토바실러스 루테리 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| JP2024504697A (ja) | 2021-01-21 | 2024-02-01 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | 肝性脳症を処置するための組成物および方法 |
| WO2022178292A1 (en) * | 2021-02-18 | 2022-08-25 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| AU2022272332A1 (en) * | 2021-05-10 | 2024-01-04 | Microba Ip Pty Ltd | Compositions and methods for treating disease |
| WO2023014048A1 (ko) * | 2021-08-02 | 2023-02-09 | 주식회사 바이오뱅크힐링 | 비피도박테리움 속 균주 또는 페디오코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351147B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 블라우티아 오베움 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331486B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 비피도박테리움 슈도카테눌라튬 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351146B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 페디오코쿠스 에시디락티시 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351148B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 페디오코쿠스 펜토사세우스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331483B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 류코노스톡 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331484B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 마실리엔시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102351145B1 (ko) * | 2021-08-02 | 2022-01-14 | 주식회사 바이오뱅크힐링 | 비피도박테리움 롱검 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102331485B1 (ko) * | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023014054A1 (ko) * | 2021-08-02 | 2023-02-09 | 주식회사 바이오뱅크힐링 | 블라우티아 속 균주, 류코노스톡 속 균주 또는 루미노코쿠스 속 균주 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102792000B1 (ko) * | 2021-10-21 | 2025-04-08 | 경북대학교 산학협력단 | 신규한 락토바실러스 루테리 psc102 균주 및 이의 용도 |
| KR102337998B1 (ko) * | 2021-11-03 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 로제부리아 파에시스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023075458A1 (ko) * | 2021-10-27 | 2023-05-04 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102337995B1 (ko) * | 2021-11-10 | 2021-12-14 | 주식회사 바이오뱅크힐링 | 아가토바쿨룸 부티리시프로두켄스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102365420B1 (ko) * | 2022-01-04 | 2022-02-23 | 주식회사 바이오뱅크힐링 | 로제부리아 인테스티날리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102444328B1 (ko) * | 2022-03-11 | 2022-09-19 | 주식회사 바이오뱅크힐링 | 아나에로스티페스 하드루스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023132628A1 (ko) * | 2022-01-04 | 2023-07-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2023176952A1 (ja) | 2022-03-18 | 2023-09-21 | 株式会社明治 | 腸管内での細菌の増殖制御用組成物及びその利用 |
| KR102626400B1 (ko) * | 2022-08-31 | 2024-01-19 | 주식회사 바이오뱅크힐링 | 도레아 론기카테나 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| KR102628942B1 (ko) * | 2023-08-08 | 2024-01-26 | 주식회사 바이오뱅크힐링 | 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| KR102620186B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 리모실락토바실러스 뮤코세 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| KR102620185B1 (ko) * | 2023-08-08 | 2024-01-04 | 주식회사 바이오뱅크힐링 | 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| WO2025033636A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2025033635A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| WO2025076184A1 (en) | 2023-10-03 | 2025-04-10 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| WO2025093777A1 (en) | 2023-11-05 | 2025-05-08 | Human Biome Institute S.A. | Functional compositions and methods of use thereof in the treatment and recurrence prophylaxis of clostridioides difficile infection and restoration of healthy microbiota |
| CN117797176B (zh) * | 2024-03-01 | 2024-07-02 | 南京大学 | 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US132A (en) | 1837-02-25 | Improvement in propelling machinery by magnetism and electro-magnetism | ||
| US4205A (en) | 1845-09-23 | Spark-arrester | ||
| US3261761A (en) | 1962-05-07 | 1966-07-19 | Arthur W Anderson | Method of freeze drying bacterial cultures |
| ES2248822T3 (es) | 1995-09-15 | 2006-03-16 | Dale N. Gerding | Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile. |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2006050479A2 (en) | 2004-11-01 | 2006-05-11 | George Mason University | Compositions and methods for diagnosing colon disorders |
| CA2599909C (en) | 2005-03-03 | 2014-12-02 | Meiji Dairies Corporation | Immune function modulating agents |
| EP2337569A4 (en) | 2008-09-25 | 2013-04-03 | Univ New York | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND RESTORING THE STOMACH DARM, SKIN AND NOSE MICROBIOTA |
| GB0916335D0 (en) | 2009-09-17 | 2009-10-28 | Martin W J | Medicaments |
| ES2730828T3 (es) | 2010-02-01 | 2019-11-12 | Rebiotix Inc | Bacterioterapia para la colitis por Clostridium difficile |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| NZ618935A (en) | 2010-08-04 | 2014-03-28 | Karma Medical Prod Co Ltd | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US9386793B2 (en) | 2010-08-20 | 2016-07-12 | New York University | Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota |
| WO2012098358A1 (en) | 2011-01-20 | 2012-07-26 | Biopharma Technology Ltd | Freeze drying method |
| CN103561575A (zh) | 2011-05-23 | 2014-02-05 | 华盛顿州立大学研究基金会 | 光合色素稳定剂在水果和蔬菜中调控成熟和质量的用途 |
| EP2744890A4 (en) | 2011-09-14 | 2015-07-08 | Univ Kingston | METHOD FOR TREATING DISORDERS OF THE MAGENDAR SYSTEM |
| EP4477750A3 (en) | 2011-12-01 | 2025-03-26 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| EP2832859B1 (en) | 2012-03-30 | 2018-07-25 | Ajinomoto Co., Inc. | Diabetes-inducible bacterium |
| WO2013171515A1 (en) | 2012-05-18 | 2013-11-21 | Genome Research Limited | Methods and groups |
| CN102743420A (zh) | 2012-06-06 | 2012-10-24 | 上海交通大学 | 改善肠道菌群结构的方法及应用 |
| WO2014029578A1 (en) | 2012-08-24 | 2014-02-27 | Haldor Topsøe A/S | Method and catalyzed filter element with improved alkali-resistance for flue gas cleaning |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| CN104955466A (zh) | 2012-11-23 | 2015-09-30 | 赛里斯治疗公司 | 协同细菌组合物和其制造方法和用途 |
| JP2016509003A (ja) | 2013-02-04 | 2016-03-24 | セレス セラピューティクス インコーポレイテッド | 組成物および方法 |
| EP2971148A4 (en) | 2013-03-14 | 2016-08-17 | Seres Therapeutics Inc | METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| US9669059B2 (en) | 2013-03-15 | 2017-06-06 | University Of Florida Research Foundation, Incorporated | Butyrogenic bacteria as probiotics to treat clostridium difficile |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| WO2015006355A2 (en) | 2013-07-09 | 2015-01-15 | Puretech Ventures, Llc | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| CA2926466C (en) | 2013-10-03 | 2021-11-16 | Frederic Bushman | Compositions comprising a defined microbiome and methods of use thereof |
| EP3074027B1 (en) * | 2013-11-25 | 2024-12-18 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| US9956282B2 (en) | 2013-12-16 | 2018-05-01 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| WO2015156419A1 (en) | 2014-04-10 | 2015-10-15 | Riken | Compositions and methods for induction of th17 cells |
| US10206958B2 (en) | 2014-04-23 | 2019-02-19 | Cornell University | Modulation of fat storage in a subject by altering population levels of christensenellaceae in the GI tract |
| EP3146065B1 (en) | 2014-05-19 | 2024-11-13 | Memorial Sloan Kettering Cancer Center | Methods and compositions for reducing clostridium difficile infection |
| SG11201703395PA (en) | 2014-10-31 | 2017-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| WO2016086161A1 (en) | 2014-11-25 | 2016-06-02 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and gvhd |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| BR112017024264B1 (pt) | 2015-05-14 | 2022-07-12 | Crestovo Holdings Llc | Composições para transplante de flora fecal e métodos de preparação e utilização das mesmas, e dispositivos para sua administração |
| CA2986203A1 (en) | 2015-05-21 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Bacterial populations for promoting health |
| WO2016201053A1 (en) | 2015-06-09 | 2016-12-15 | Regents Of The University Of Minnesota | Methods for detecting risk of having a bloodstream infection and compositions for reducing the risk |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| PT3360559T (pt) | 2015-06-15 | 2020-01-06 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| PL3307288T3 (pl) | 2015-06-15 | 2019-12-31 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| JP2018519295A (ja) | 2015-06-22 | 2018-07-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 粘膜固有層調節性ｔ細胞の誘導 |
| HK1259347A1 (zh) | 2015-07-08 | 2019-11-29 | 赛里斯治疗公司 | 治疗结肠炎的方法 |
| EP3341000A4 (en) | 2015-08-24 | 2019-02-20 | Nubyiota LLC | SYSTEMS AND METHOD FOR TREATING DYSBIOSIS WITH BACTERIAL POPULATIONS FROM FECALIA |
| JP2018535254A (ja) | 2015-10-26 | 2018-11-29 | クレストヴォ・ホールディングス・エルエルシー | 便微生物叢関連療法のための組成物及び方法 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| HUE036362T2 (hu) | 2015-11-20 | 2018-07-30 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP4233884A3 (en) | 2015-11-24 | 2023-10-04 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| PL3313423T3 (pl) | 2016-03-04 | 2019-09-30 | 4D Pharma Plc | Kompozycje zawierające szczepy bakteryjne blautia do leczenia nadwrażliwości trzewnej |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| MX2018015522A (es) | 2016-06-14 | 2019-07-12 | Vedanta Biosciences Inc | Tratamiento de infeccion por clostridium difficile. |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| WO2018005606A1 (en) | 2016-06-28 | 2018-01-04 | Synthetic Biologics, Inc. | Microbiome protection from oral antibiotics |
| WO2018080477A1 (en) | 2016-10-26 | 2018-05-03 | The Joan & Irwin Jacobs Technion-Cornell Institute | Systems and methods for ultra-fast identification and abundance estimates of microorganisms using a kmer-depth based approach and privacy-preserving protocols |
| BR112020023933A2 (pt) | 2018-05-24 | 2021-04-27 | Seres Therapeutics, Inc. | composições bacterianas projetadas e usos destas |
| AU2019321681A1 (en) | 2018-08-17 | 2021-02-25 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| JP2024504697A (ja) | 2021-01-21 | 2024-02-01 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | 肝性脳症を処置するための組成物および方法 |
-
2017
- 2017-06-14 MX MX2018015522A patent/MX2018015522A/es unknown
- 2017-06-14 KR KR1020237023016A patent/KR102658297B1/ko active Active
- 2017-06-14 PT PT178140240T patent/PT3468573T/pt unknown
- 2017-06-14 EP EP17814024.0A patent/EP3468573B1/en active Active
- 2017-06-14 ES ES17814024T patent/ES2960053T3/es active Active
- 2017-06-14 EP EP23188649.0A patent/EP4282489A3/en active Pending
- 2017-06-14 JP JP2019518374A patent/JP7168558B2/ja active Active
- 2017-06-14 AU AU2017285211A patent/AU2017285211B2/en active Active
- 2017-06-14 WO PCT/US2017/037498 patent/WO2017218680A1/en not_active Ceased
- 2017-06-14 KR KR1020197001044A patent/KR102554351B1/ko active Active
- 2017-06-14 DK DK17814024.0T patent/DK3468573T5/da active
- 2017-06-14 CA CA3027917A patent/CA3027917C/en active Active
- 2017-06-14 CN CN201780049780.0A patent/CN109562133A/zh active Pending
- 2017-06-14 CA CA3226196A patent/CA3226196A1/en active Pending
- 2017-06-14 KR KR1020257031130A patent/KR20250140643A/ko active Pending
- 2017-06-14 KR KR1020247012234A patent/KR102862927B1/ko active Active
- 2017-06-14 FI FIEP17814024.0T patent/FI3468573T3/fi active
-
2018
- 2018-12-13 MX MX2023003461A patent/MX2023003461A/es unknown
-
2022
- 2022-10-27 JP JP2022172637A patent/JP7483828B2/ja active Active
-
2023
- 2023-05-31 US US18/326,511 patent/US12390498B2/en active Active
-
2024
- 2024-05-01 JP JP2024074166A patent/JP2024109615A/ja active Pending
- 2024-08-29 AU AU2024216443A patent/AU2024216443A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517828A5 (enExample) | ||
| JP2019048857A5 (enExample) | ||
| JP2018199695A5 (enExample) | ||
| FI3468573T3 (fi) | Clostridium difficile -infektion hoito | |
| JP2021078504A5 (enExample) | ||
| RU2020132171A (ru) | Новая бифидобактерия, характеризующаяся различными функциями, и ее применение | |
| HRP20191344T1 (hr) | Sastavi koji sadrže bakterijske sojeve | |
| SI3209310T1 (en) | Compositions containing bacterial strains | |
| JP2019001815A5 (enExample) | ||
| JP2019108378A5 (enExample) | ||
| JP2016509003A5 (enExample) | ||
| HRP20191096T1 (hr) | Sastavi koje sadrže bakterijske blautia sojeve za liječenje visceralne hipersenzitivnosti | |
| JP2020520916A5 (enExample) | ||
| HRP20220578T1 (hr) | Pripravci koji sadrže bakterijske sojeve | |
| JP2015517488A5 (enExample) | ||
| JP2016539119A5 (enExample) | ||
| JP2012524548A5 (enExample) | ||
| HRP20210780T1 (hr) | Pripravci koji sadrže bakterijske sojeve | |
| NZ713423A (en) | Bacteriophage therapy | |
| JP2015525566A5 (enExample) | ||
| JP2016539105A5 (enExample) | ||
| RU2019130941A (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
| RU2011133824A (ru) | Фармацевтическая композиция для защиты животного от растройства, возникающего в результате инфекции бактерий, которая относится к группе нокардиоформных актиномицетов | |
| JP2020529431A5 (enExample) | ||
| JP2014113137A5 (enExample) |